OGN vs SANA · P/E 3.4, rev $3.02B vs $846.0M cap
Organon & Co (OGN) versus Sana Biotechnology Inc (SANA) — a side-by-side from cached financials, not a winner call.
Organon & Co (OGN) is a drug manufacturers - general company listed on US.
Sana Biotechnology Inc (SANA) is a biotechnology company listed on NASDAQ.
Latest reported OGN revenue for 2026-06-30 was $3.02B. Net income was $254.0M. OGN currently screens at market cap $2.52B and trailing P/E 3.4.
SANA does not have a complete income-statement cache yet.
OGN currently screens at market cap $2.52B and trailing P/E 3.4. SANA currently screens at market cap $846.0M.
Not investment advice. Open the OGN and SANA stock pages for the full models.
Not investment advice.